Chemed Q2 adjusted EPS $4.27 (-21.9% YoY); cuts FY2025 guidance; VITAS CEO departs

CHEMED CORP

2025-Q2 EPS reported $8.43 revenue$1,265,741,000

GAAP EPS $3.57 (-23.2%); adjusted EPS $4.27 (-21.9%); revenue $618.8M (+3.8%).
VITAS adjusted EBITDA margin ex-Medicare cap 16.2% (-163 bps); Florida cap accrual $16.4M.
Roto-Rooter adjusted EBITDA margin 21.8% (-517 bps); revenue +0.6% to $222.6M.
FY2025 adjusted EPS guidance cut to $22.00-$22.30 from $24.95-$25.45; prior year $23.13.
VITAS CEO Nicholas Westfall resigns eff. July 29, 2025; Joel Wherley named successor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.